TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid

Related Keywords

Russia , Japan , Tokyo , New Zealand , Canada , Australia , China , United Kingdom , Great Britain , Gewinn Nur , S Libby Holman , Chuck Triano , Jack Cox , Linkedin , Twitter , Eisai Inc , European Medicines Agency , Washington University School Of Medicine , National Institute On , National Institutes Of Health , Communications Department , Health Canada On , Eisai Europe Ltd , Regulatory Agency , Facebook , Alzheimer Network Trials Unit , Eisai Co Ltd , National Institute For Health , Exchange Commission , Youtube , Alzheimer Clinical Trial Consortium , Investor Relations Department , United Nations Sustainable Development Goals Sdgs , Biogen Inc , Public Relations Department , Drug Administration , National Medical Products Administration , Ministry Of Health , Devices Agency , Marketing Authorization Application , United Kingdom Medicines , Innovative Licensing , Access Pathway , National Institute , Care Excellence , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Medical Devices Agency , New Drug Submission , Health Canada , Clinical Trial Consortium , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Corporate Concept , United Nations Sustainable Development Goals , Private Securities Litigation Reform Act , Eisai , Ubmits , Arketing , Authorization , Pplication , Lecanemab , Reatment , Early , Lzheimer , Isease , Reat , Ritain ,